Literature DB >> 22634619

Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion.

Irina G Luzina1, Edward M Pickering, Pavel Kopach, Phillip H Kang, Virginia Lockatell, Nevins W Todd, John C Papadimitriou, Andrew N J McKenzie, Sergei P Atamas.   

Abstract

Expression of IL-33 is elevated in patients with pulmonary diseases, and full-length (not proteolytically processed) IL-33 is the predominant form in the lungs in health and disease. To determine whether activation of IL-33 is needed for functional effects, activities of full-length mouse and mature mouse (mm) forms of IL-33 were compared in vivo. Replication-deficient adenoviral constructs were used for gene delivery. Both isoforms caused pulmonary infiltration of lymphocytes and neutrophils, whereas mm IL-33 also caused pulmonary eosinophilia and goblet cell hyperplasia and increased expression of IL-4, IL-5, IL-13, IL-17, MCP-1, and KC. The different effects were not associated with differential release from IL-33-producing cells or by differences in subcellular distributions of IL-33 isoforms. Germline deficiency of the cell surface receptor chain ST2 abrogated the mm IL-33-induced Th2-associated effects (pulmonary eosinophilia, goblet cell hyperplasia, and increased IL-4 and IL-5), yet the lymphocytic infiltration induced by full-length mouse IL-33 or mm IL-33 was not fully abrogated by the absence of ST2. The similar effects of IL-33 isoforms were associated with comparable regulation of gene expression, notably matrix metalloproteinases 3, 10, and 13. Thus, full-length IL-33 is functionally active in vivo in an ST2-independent fashion, and its effects are partially different from those of mature IL-33. The different effects of these isoforms, particularly the pro-Th2 effects of mature IL-33, are due to differential utilization of the IL-33R chain ST2, whereas their similar effects result from regulation of gene expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634619      PMCID: PMC3381874          DOI: 10.4049/jimmunol.1200259

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation.

Authors:  Jennifer Louten; Andrew L Rankin; Ying Li; Erin E Murphy; Maribel Beaumont; Christina Moon; Patricia Bourne; Terrill K McClanahan; Stefan Pflanz; Rene de Waal Malefyt
Journal:  Int Immunol       Date:  2011-03-21       Impact factor: 4.823

2.  Alternatively spliced variants of interleukin-4 promote inflammation differentially.

Authors:  Irina G Luzina; Virginia Lockatell; Nevins W Todd; Kendrick Highsmith; Achsah D Keegan; Jeffrey D Hasday; Sergei P Atamas
Journal:  J Leukoc Biol       Date:  2011-02-01       Impact factor: 4.962

3.  Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts.

Authors:  Masatsugu Kurokawa; Satoshi Matsukura; Mio Kawaguchi; Koushi Ieki; Shintaro Suzuki; Miho Odaka; Shin Watanabe; Tetsuya Homma; Masayuki Sato; Munehiro Yamaguchi; Hiroko Takeuchi; Mitsuru Adachi
Journal:  Int Arch Allergy Immunol       Date:  2011-06-01       Impact factor: 2.749

4.  Splice isoforms of human interleukin-4 are functionally active in mice in vivo.

Authors:  Irina G Luzina; Virginia Lockatell; Nevins W Todd; Achsah D Keegan; Jeffrey D Hasday; Sergei P Atamas
Journal:  Immunology       Date:  2011-01-10       Impact factor: 7.397

5.  Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.

Authors:  Koichi Yanaba; Ayumi Yoshizaki; Yoshihide Asano; Takafumi Kadono; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2011-01-19       Impact factor: 2.980

6.  Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice.

Authors:  Xiang Zhiguang; Chen Wei; Ravary Steven; Dong Wei; Zhang Wei; Mu Rong; Li Zhanguo; Zhang Lianfeng
Journal:  Immunol Lett       Date:  2010-04-20       Impact factor: 3.685

Review 7.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

8.  Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages.

Authors:  Amrita D Joshi; Sameer R Oak; Adam J Hartigan; William G Finn; Steven L Kunkel; Karen E Duffy; Anuk Das; Cory M Hogaboam
Journal:  BMC Immunol       Date:  2010-10-19       Impact factor: 3.615

9.  Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease.

Authors:  John V Gosselink; Shizu Hayashi; W Mark Elliott; Li Xing; Becky Chan; Luojia Yang; Claire Wright; Don Sin; Peter D Paré; John A Pierce; Richard A Pierce; Alex Patterson; Joel Cooper; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2010-01-14       Impact factor: 21.405

10.  Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation.

Authors:  Shafaqat Ali; Dang Quan Nguyen; Werner Falk; Michael Uwe Martin
Journal:  Biochem Biophys Res Commun       Date:  2009-12-24       Impact factor: 3.575

View more
  59 in total

Review 1.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

Review 2.  Interleukin 33: a switch-hitting cytokine.

Authors:  Daniel O Villarreal; David B Weiner
Journal:  Curr Opin Immunol       Date:  2014-04-22       Impact factor: 7.486

3.  IL-33-induced neutrophil extracellular traps degrade fibronectin in a murine model of bronchopulmonary dysplasia.

Authors:  Rui Jin; Junjie Xu; Qianqian Gao; Xiaonan Mao; Jiao Yin; Keyu Lu; Yan Guo; Mingshun Zhang; Rui Cheng
Journal:  Cell Death Discov       Date:  2020-05-04

4.  The TLR4-TRIF pathway can protect against the development of experimental allergic asthma.

Authors:  Karim H Shalaby; Saba Al Heialy; Kimitake Tsuchiya; Soroor Farahnak; Toby K McGovern; Paul-Andre Risse; Woong-Kyung Suh; Salman T Qureshi; James G Martin
Journal:  Immunology       Date:  2017-06-20       Impact factor: 7.397

5.  Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis.

Authors:  Jessica C Garbern; Jason Williams; Amy C Kristl; Alyyah Malick; Inbal Rachmin; Benjamin Gaeta; Nafis Ahmed; Ana Vujic; Peter Libby; Richard T Lee
Journal:  J Mol Cell Cardiol       Date:  2019-02-11       Impact factor: 5.000

6.  IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism.

Authors:  Pavel Kopach; Virginia Lockatell; Edward M Pickering; Ronald E Haskell; Richard D Anderson; Jeffrey D Hasday; Nevins W Todd; Irina G Luzina; Sergei P Atamas
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

7.  Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity.

Authors:  Daniel O Villarreal; Megan C Wise; Jewell N Walters; Emma L Reuschel; Min Joung Choi; Nyamekye Obeng-Adjei; Jian Yan; Matthew P Morrow; David B Weiner
Journal:  Cancer Res       Date:  2014-01-21       Impact factor: 12.701

Review 8.  IL-25/IL-33/TSLP contributes to idiopathic pulmonary fibrosis: Do alveolar epithelial cells and (myo)fibroblasts matter?

Authors:  Xuefeng Xu; Jinglan Zhang; Huaping Dai
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-04

9.  The full-length interleukin-33 (FLIL33)-importin-5 interaction does not regulate nuclear localization of FLIL33 but controls its intracellular degradation.

Authors:  Andrew Clerman; Zahid Noor; Rita Fishelevich; Virginia Lockatell; Brian S Hampton; Nirav G Shah; Mariah V Salcedo; Nevins W Todd; Sergei P Atamas; Irina G Luzina
Journal:  J Biol Chem       Date:  2017-11-10       Impact factor: 5.157

10.  Interleukin-33 exacerbates acute colitis via interleukin-4 in mice.

Authors:  Peter N Pushparaj; Dong Li; Mousa Komai-Koma; Rodrigo Guabiraba; James Alexander; Charles McSharry; Damo Xu
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.